Harvest Portfolios Group Inc. Purchases 1,500 Shares of Sanofi (NASDAQ:SNY)

Harvest Portfolios Group Inc. increased its holdings in shares of Sanofi (NASDAQ:SNY) by 4.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,200 shares of the company’s stock after buying an additional 1,500 shares during the period. Harvest Portfolios Group Inc.’s holdings in Sanofi were worth $2,144,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its stake in Sanofi by 773.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,651 shares of the company’s stock worth $275,000 after acquiring an additional 5,004 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Sanofi by 7.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,618 shares of the company’s stock valued at $2,411,000 after buying an additional 3,268 shares during the period. Larson Financial Group LLC lifted its position in shares of Sanofi by 480.8% during the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after buying an additional 500 shares during the last quarter. Geneos Wealth Management Inc. lifted its holdings in Sanofi by 9.0% during the first quarter. Geneos Wealth Management Inc. now owns 7,063 shares of the company’s stock valued at $343,000 after purchasing an additional 582 shares during the last quarter. Finally, Gallacher Capital Management LLC increased its stake in shares of Sanofi by 14.4% in the first quarter. Gallacher Capital Management LLC now owns 6,686 shares of the company’s stock worth $325,000 after purchasing an additional 843 shares in the last quarter. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Argus boosted their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Stock Performance

SNY opened at $51.26 on Thursday. The company’s 50 day moving average is $55.78 and its 200 day moving average is $52.15. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The company has a market cap of $130.09 billion, a price-to-earnings ratio of 26.15, a PEG ratio of 1.35 and a beta of 0.61. Sanofi has a 12-month low of $45.00 and a 12-month high of $58.97.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same period in the previous year, the firm earned $2.55 EPS. The firm’s revenue was up 12.3% compared to the same quarter last year. On average, equities research analysts predict that Sanofi will post 4.27 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.